IONSIonis Pharmaceuticals, Inc.

IONS Stock Price, Valuation & Chart | Ionis Pharmaceuticals, Inc.

Compare

$59.880-0.48 (-0.80%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IONS intrinsic value IONS calculated fair value vs price

Overview Financials Dividends Ratios

IONS Historical price chart

IONS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization9.95B

PE Ratio-34.81

EPS-1.72

Trading Volume1.87M

Today's High/Low60.99/59.78

Dividend Yield0.00

52 Week High/Low86.74/49.13

Shares Outstanding166.18M

IONS Financial Statement

IONS Analyst ratings

IONS Analysis & performance metrics

IONS Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric…

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial…

IONS Management team

Name

Position

C. Frank Bennett BSc, Ph.D.

Executive Vice President & Chief Scientific Officer

Hayley Soffer

Vice President of Corporate Communications

Elizabeth L. Hougen M.A., M.B.A., M.S.CFO

Executive Vice President of Finance & Chief Financial Officer

Patrick R. O'Neil Esq.

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

Kyle Jenne

Executive Vice President & Chief Global Product Strategy Officer

D. Wade Walke Ph.D.

Senior Vice President of Investor Relations

Richard S. Geary Ph.D.

Executive Vice President & Chief Development Officer

Tracy Berns J.D.

Senior Vice President and Chief Compliance & Quality Assurance Officer

Name

Position

C. Frank Bennett BSc, Ph.D.

Executive Vice President & Chief Scientific Officer

Hayley Soffer

Vice President of Corporate Communications

Elizabeth L. Hougen M.A., M.B.A., M.S.CFO

Executive Vice President of Finance & Chief Financial Officer

Patrick R. O'Neil Esq.

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

Kyle Jenne

Executive Vice President & Chief Global Product Strategy Officer

D. Wade Walke Ph.D.

Senior Vice President of Investor Relations

Richard S. Geary Ph.D.

Executive Vice President & Chief Development Officer

Tracy Berns J.D.

Senior Vice President and Chief Compliance & Quality Assurance Officer

Management Team

C. Frank Bennett BSc, Ph.D.

Executive Vice President & Chief Scientific Officer

Hayley Soffer

Vice President of Corporate Communications

Elizabeth L. Hougen M.A., M.B.A., M.S.CFO

Executive Vice President of Finance & Chief Financial Officer

Patrick R. O'Neil Esq.

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

Kyle Jenne

Executive Vice President & Chief Global Product Strategy Officer

D. Wade Walke Ph.D.

Senior Vice President of Investor Relations

Richard S. Geary Ph.D.

Executive Vice President & Chief Development Officer

Tracy Berns J.D.

Senior Vice President and Chief Compliance & Quality Assurance Officer

Management

C. Frank Bennett BSc, Ph.D.

Executive Vice President & Chief Scientific Officer

Hayley Soffer

Vice President of Corporate Communications

Elizabeth L. Hougen M.A., M.B.A., M.S.CFO

Executive Vice President of Finance & Chief Financial Officer

Patrick R. O'Neil Esq.

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

Kyle Jenne

Executive Vice President & Chief Global Product Strategy Officer

D. Wade Walke Ph.D.

Senior Vice President of Investor Relations

Richard S. Geary Ph.D.

Executive Vice President & Chief Development Officer

Tracy Berns J.D.

Senior Vice President and Chief Compliance & Quality Assurance Officer

Total 8 executives

IONS Frequently asked questions

What is Ionis Pharmaceuticals, Inc. (IONS) Stock Price?

Current stock price of Ionis Pharmaceuticals, Inc. (IONS) stock is $59.880. The stock price is -0.80% lower in the session. The intraday range can be seen from this page. Volume of Ionis Pharmaceuticals, Inc. (IONS) stock is 1.87M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Ionis Pharmaceuticals, Inc. (IONS) stock price going up or down today?

The stock price of Ionis Pharmaceuticals, Inc. (IONS) can change with earnings, company news, and overall market sentiment. Ionis Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Ionis Pharmaceuticals, Inc. stock expensive at its current price?

Whether Ionis Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IONS on this page is -34.81. EPS on this page is -1.72. Compare those figures with peers and growth expectations before deciding if the current Ionis Pharmaceuticals, Inc. price is justified.

How has the stock price of Ionis Pharmaceuticals, Inc. (IONS) performed historically?

Historical performance for Ionis Pharmaceuticals, Inc. (IONS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IONS reacted to past earnings and market events.

Should I buy Ionis Pharmaceuticals, Inc. (IONS) stock, at this price?

Buying Ionis Pharmaceuticals, Inc. (IONS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.